An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody in Acquired Hemophilia A
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
To evaluate the time of response, sustained remission rate and relapse rate of CD38
monoclonal antibody (Daratumumab) in the treatment of AHA. To evaluate the safety of CD38
monoclonal antibody in the treatment of AHA.